Skip to content

13 results for "Meta-analysis: What did research on PTSD find in June 2026?"

Ketamine-assisted psychotherapy for posttraumatic stress disorder: a systematic review and individual participant data meta-analysis of predictors of treatment effects.

Psychotherapy and Psychosomatics June 19, 2026 Judith Rohde, Tyler M Moore, Kathryn Walker et al.

Ketamine combined with psychotherapy has shown promise in treating posttraumatic stress disorder (PTSD), but predictors of clinical benefit remain unclear. In this systematic review and individual participant data meta-analysis (IPDMA), we examined patient- and treatment-level predictors of PTSD symptom change after combined treatment. Eligible studies combined ketamine with psychotherapy in...

At-Home Telehealth-Supported Subcutaneous Ketamine Therapy in Adults With Moderate to Severe Depression, Anxiety, or PTSD: A Real-World Observational Study of Safety, Feasibility, and Clinical Outcomes in a Large, Heterogeneous Cohort in the United States.

Journal of Medical Internet Research June 17, 2026 Acacia C Parks, Amanda L Woodward, Robert D Henry et al.

Background: Depression, anxiety,, and PTSD are leading global causes of disability. Standard interventions utilize slow mechanisms of action, high attrition, and significant accessibility barriers. While intravenous (IV) and intranasal ketamine are rapid-acting alternatives, high cost and intensive logistical requirements limit adoption. Sublingual (SL) at-home ketamine addresses some gaps but...

Efficacy of Mindfulness-Based Interventions for Treating Anxiety in PTSD Patients

Journal of Health Wellness and Community Research June 16, 2026 Saba Naz, Bakht E Karam, Wahaj Ahmad Khan et al.

Background: Post-traumatic stress disorder is frequently accompanied by persistent anxiety, hyperarousal, sleep disturbance, and impaired emotional regulation. Mindfulness-based interventions may support trauma-exposed patients by improving present-moment awareness, distress tolerance, and regulation of intrusive thoughts and bodily arousal. Objective: This study evaluated whether an eight-week...

Acute pretrauma ethanol exacerbates PTSD-like phenotype in rats and is reversed by early intranasal ketamine

Scientific Reports June 14, 2026 Bar Eilat Yogev, Gal Levi, Noa Efroni et al.

Alcohol consumption before trauma is a prevalent but understudied risk factor for posttraumatic stress disorder (PTSD). This study investigated whether acute ethanol exposure prior to trauma modulates PTSD-like symptom development in rats, identified hippocampal mechanisms involved, and tested an early post-trauma intervention. Adult male Sprague-Dawley rats received ethanol (1.6 g/kg, 40% v/v,...

Psychedelic-Assisted Psychotherapy for the Treatment of PTSD: A Systematic Review and Meta-Analysis

Psychoactives June 8, 2026 Fizza Mitter, Anton Sheptooha, Janni Leung et al.

Post-traumatic stress disorder (PTSD) remains inadequately treated by existing pharmacological and psychological interventions, prompting growing interest in psychedelic-assisted psychotherapy. Although randomised controlled trials have evaluated several psychedelic agents for PTSD, to our knowledge, no prior PTSD-specific synthesis has quantitatively examined multiple agent classes within a...

Factors associated with post-traumatic growth in severe COVID-19 patients discharged from intensive care: the influence of near-death experiences.

Scientific Reports June 5, 2026 Amaury C Mengin, Julie Rolling, Walid Oulehri et al.

Intensive Care Unit (ICU) hospitalizations confront individuals with imminent death and may cause post-traumatic stress disorder (PTSD). In contrast, traumatic events may lead to positive psychological outcomes such as post-traumatic growth. As consciousness is altered, near-death experiences (NDEs) may occur and be associated with post-traumatic growth. Our cross-sectional, monocentric study...

Clinical Outcomes of Ketamine Therapy for Depression, Anxiety, and PTSD in Post-TBI Patients

European Psychiatry June 1, 2026 W. Aldulaimy, A. Shah

Introduction TBI patients often suffer from severe, treatment-resistant depression and PTSD. Ketamine shows promise in non-TBI populations, but its efficacy in TBI patients needs exploration for efficacy and tolerability. Objectives Evaluate ketamine’s clinical effectiveness and safety (PHQ-9, GAD-7, PCL-5 scores) in post-TBI patients, comparing IM, intranasal, and oral routes. Methods Design:...

Circuit-informed modulation of traumatic memory in PTSD: integrating extinction, suppression, and reconsolidation.

Molecular Psychiatry June 1, 2026 Xin Yi, Yuan-Bo Zhang, Tong-Zhou Yu et al.

Post-traumatic stress disorder (PTSD) persists when stress biases memory systems-broadening threat engrams, weakening context-appropriate inhibition, and rendering extinction fragile. Integrating preclinical and human evidence, we argue that these liabilities are tractable within a circuit-informed framework that aligns behavioral procedures with the biology of fear memory. Extinction can be...

Characteristics of Sleep Paralysis and Its Association With PTSD, Stress, and Other Lifestyle Variables Among the Population of Pakistan, a Cross-Sectional Study.

Public health challenges June 1, 2026 Alishba Javaid, Rabi Jan, Afifa Khan et al.

Sleep paralysis (SP) is a parasomnia disorder connected to being unable to move your body though the experiencing person remains conscious. Factors involving this disorder are stress, post-traumatic stress disorder (PTSD), lifestyle factors including the amount of sleep, and the amount of caffeine consumed. Our study aim is to assess the symptoms, duration, time of occurrence, and body position...

The impact of ketamine on posttraumatic stress disorder (PTSD) symptomatology in trauma-exposed populations: a narrative review.

Journal of trauma and injury June 1, 2026 Minaal Ahmed Malik, Michele Halasa, Jack Chia et al.

Ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, is widely used in trauma and emergency medicine for its rapid analgesic and sedative properties. While its efficacy in acute pain management is well established, concerns persist regarding its long-term psychological effects, particularly its potential role in the development of posttraumatic stress disorder (PTSD). Some studies...

Investigational drugs in PTSD.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology June 1, 2026 Ted Obi, Kerry J. Ressler

Post-traumatic stress disorder (PTSD) remains one of psychiatry's most challenging disorders, common, disabling, and biologically complex. Despite decades of research, only sertraline and paroxetine are FDA-approved, both with modest efficacy. Even first-line trauma-focused psychotherapies leave up to half of patients with persistent symptoms. However, advances in neurobiology are reframing...

From therapeutic promise to evidentiary discipline: Reassessing MDMA-assisted psychotherapy for posttraumatic stress disorder.

Journal of Traumatic Stress June 1, 2026 Kadek Suhardita, Veno Dwi Krisnanda, Rikas Saputra et al.

In this commentary on Morland et al. (2026)'s recent State of the Science article on 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for posttraumatic stress disorder (PTSD), we aim to emphasize both MDMA's therapeutic promise and its unresolved scientific challenges. Although recent trials on MDMA-assisted interventions have reported encouraging reductions in PTSD symptoms, the...